Clortalidona

Quick links to important sections

Clortalidona

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clortalidona

Quick Facts

Property Description
Active ingredient Chlorthalidone (INN)
Form Oral Tablet
Pharmacological class Diuretic (Thiazide-like)
General purpose Fluid balance, blood pressure support
Origin Synthetic (Phthalimidine derivative)

What Type of Medicine is Clortalidona?

Clortalidona, with the official active substance Chlorthalidone, is a potent, synthetic medication classified as both an antihypertensive agent and a Diuretic. It belongs to the Thiazide-like Diuretic (TLD) pharmacological class, a category noted for its structural difference from traditional thiazides. This distinction is significant: Chlorthalidone is chemically a phthalimidine derivative, a structure that is clinically recognized for contributing to a significantly longer duration of action compared to many alternatives.

Composition and General Therapeutic Purpose

The core composition is the single-ingredient compound Chlorthalidone, which is administered as an oral tablet and chemically contains a sulfonamide group. The overall general purpose of this medicine is to act as a water pill, helping the body eliminate excess sodium and fluid. This action is crucial for achieving volume reduction and consistently lowering systemic blood pressure, which is the fundamental benefit.

Chlortalidona is distinguished as a highly effective long-acting diuretic agent, providing a sustained therapeutic effect that typically lasts over 48 hours. This property allows for stable fluid and electrolyte balance, reinforcing its use as a preferred first-line agent for consistent antihypertensive control.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH: National Library of Medicine

What side effects are possible with Clortalidona?

Officially Documented Safety Concerns and Adverse Reactions

The safety profile of Clortalidona (Chlorthalidone) is primarily defined by the risk of Metabolic and Electrolyte Imbalances, which are commonly observed. The most frequent reactions include Hypokalemia (low potassium), Hyponatremia (low sodium), Hyperglycemia (high blood sugar), and Hyperuricemia (high uric acid), reflecting the drug's mechanism as a diuretic.

System-Organ Class Common Adverse Reactions
Metabolic Hypokalemia, Hyponatremia, Hyperglycemia
Vascular/Nervous Orthostatic Hypotension, Dizziness, Headache
Gastrointestinal Anorexia, Gastric Irritation, Nausea, Vomiting

Rare and Serious Adverse Reactions

While uncommon, regulatory documents note the potential for serious adverse reactions. These include severe hematologic conditions such as Aplastic Anemia, Agranulocytosis, and Thrombocytopenia. Rare effects also span Pancreatitis and Intrahepatic Cholestatic Jaundice. In patients with pre-existing hepatic impairment, minor fluid changes may lead to a risk of precipitating Hepatic Coma.

Population-Specific Safety Considerations

The medicine is generally Contraindicated in individuals with Anuria (inability to urinate) or a known hypersensitivity to chlorthalidone or any other sulfonamide-derived drug. Use is not recommended during Pregnancy or Lactation due to the potential for adverse fetal or infant effects. Additionally, caution is required in patients with Renal or Hepatic Impairment due to the increased risk of cumulative effects and severe complications.

Overdose and Emergency Response

Overdose and when to seek help

Acute overdosage with Chlorthalidone (Clortalidona) is formally documented in regulatory prescribing information, detailing specific clinical manifestations and mandated emergency actions.

Official labeling states that overdose may present with signs such as nausea, weakness, dizziness, drowsiness, muscle pain, and extreme thirst. More severe outcomes are tied to systemic depletion, including severe hypotension (markedly low blood pressure) and critical disturbances of electrolyte balance. These documented laboratory findings often include significant hypokalemia (low potassium) and hyponatremia (low sodium), which require urgent clinical management.

Regulators consistently mandate that individuals must seek immediate medical attention or contact emergency services immediately following any suspected overdose. This requirement is due to the potential for severe, life-threatening electrolyte abnormalities and cardiovascular instability.

The official product information specifies that no specific antidote is known to exist for Chlorthalidone. Management procedures described in regulatory texts are symptomatic and supportive, and typically include initiating gastric lavage. Supportive measures often involve careful monitoring of electrolyte levels and the administration of intravenous fluids, such as dextrose-saline with potassium, to stabilize the patient and correct the officially documented metabolic deficits.

Therapeutic Uses of Clortalidona

Clortalidona is a thiazide-like diuretic, commonly known as a 'water pill,' primarily prescribed for the management of high blood pressure (hypertension) and the reduction of fluid retention (edema).

Clortalidona is indicated for both the management of hypertension, used alone or with other agents, and as an adjunct therapy for edema. The benefit of clortalidona is that it assists the kidneys in promoting the removal of excess salt and water from the body. This process may assist in reducing blood pressure and easing swelling.

The drug is used to manage edema associated with several serious conditions, including mild-to-moderate congestive heart failure, certain types of renal disease, and hepatic cirrhosis with ascites. By addressing blood pressure and pathological fluid retention, clortalidona may reduce the overall strain on the heart and blood vessels.

Quick Fact: Relief for Pathological Fluid Retention

Regulatory References

  1. APO-CHLORTHALIDONE (chlorthalidone) is indicated

Eligibility and Restrictions for Use

Who can and cannot use Clortalidona?

The official eligibility profile for Clortalidona (Chlorthalidone) is strictly defined by regulatory authorities based on pre-existing conditions and population status.


Absolute Contraindications

Use is prohibited in individuals with:

  • Anuria (absence of urine production).
  • Documented hypersensitivity to the active substance, Clortalidona.
  • Documented hypersensitivity to any other sulfonamide-derived drugs.
  • Severe renal or hepatic failure and refractory hyponatremia are also listed as contraindications in some regulatory regions.

Restricted or Conditional Use

Use requires caution and monitoring in several populations:

  • Patients with impaired hepatic function or progressive liver disease, as fluid and electrolyte changes may risk precipitating hepatic coma.
  • Patients with severe renal disease, where drug effects can be cumulative and may precipitate azotemia.
  • Individuals susceptible to gout or hyperuricemia, as the drug may exacerbate these conditions.

Age and Reproductive Status Limitations

  • Pediatric Patients: Safety and effectiveness have not been conclusively established; therefore, use is not recommended.
  • Pregnancy: The drug should be used only if clearly needed, as it carries potential fetal risks.
  • Lactation: Use is not recommended for breastfeeding women, as Clortalidona is known to pass into human milk.

What should I know about interactions with other medicines?

Clortalidona is a thiazide-like diuretic that can interact with various medications, primarily by affecting blood pressure, electrolyte balance, or the kidney’s ability to clear certain substances.

Potential Drug Interactions

Interacting Product Category Key Effect and Note
Lithium Increased risk of Lithium toxicity. Clortalidona can reduce the kidney's ability to excrete lithium, leading to dangerously high levels. Frequent monitoring of serum lithium levels is mandatory during co-administration.
Other Antihypertensive Drugs Potentiation of blood pressure-lowering effect. The combination can lead to an additive effect, which may result in excessive lowering of blood pressure.
Antidiabetic Agents (Insulin, Oral Agents) Altered dosage requirements. Clortalidona may cause an increase in blood glucose levels, potentially requiring adjustment of insulin or oral hypoglycemic agent dosages in diabetic patients.
Non-depolarizing Skeletal Muscle Relaxants Increased responsiveness. The effect of drugs like tubocurarine may be enhanced.
Norepinephrine Decreased arterial responsiveness. Clortalidona may lessen the arteries' response to norepinephrine, although this is usually not enough to prevent the pressor agent from being effective for therapeutic use.

Patients should inform their healthcare provider of all prescription, non-prescription, and herbal products used to safely manage any potential interactions.

Mechanism of Action

How Clortalidona Works: Mechanism of Action

Clortalidona exerts its physiological action through two primary mechanistic domains, beginning with the kidney's salt handling system. The molecule functions as an inhibitor of the Sodium-Chloride Symporter (NCC), a primary transport protein located on the cells of the Distal Convoluted Tubule (DCT). The molecular blockade of the NCC prevents the reuptake of Na^+ and Cl^- ions, creating an osmotic gradient that retains water within the kidney tubule. This fundamental cascade leads directly to sustained natriuresis (salt excretion) and diuresis (water excretion), which results in a net reduction of the Extracellular Fluid Volume.

Beyond fluid loss, the drug engages a separate, volume-independent mechanism involving the direct relaxation of smooth muscle cells in peripheral blood vessels, which may be influenced by its inhibitory effect on Carbonic Anhydrase. This action results in a sustained decrease in Peripheral Vascular Resistance (PVR). The action on the NCC also modulates systemic electrolyte balance, notably causing increased excretion of potassium and magnesium, while being characterized by a decrease in calcium excretion. The resulting fluid volume reduction simultaneously triggers compensatory activation of the Renin-Angiotensin-Aldosterone System (RAAS), defining a key mechanism limitation.

Dosage and Administration Information

Instruction Map: How to use Chlorthalidone (Clortalidona) — Administration Guidelines


Administration Scope

Category Instruction
Route of administration Oral route only, administered as a tablet.
Dosing schedule (Adults) Hypertension: Initial dose is 12.5 mg or 25 mg once daily; dose may be doubled after 2 to 4 weeks, up to a maximum of 100 mg daily. Edema: Initial dose is 50 mg to 100 mg once daily, or 100 mg every other day, with a maximum dose of 200 mg daily.
Timing in relation to meals Recommended to be taken with food.
Preparation requirements None; no dilution or reconstitution is required for the oral tablet.
Age-group administration rules Pediatrics: Safety and effectiveness have not been formally established. Older Adults: Dose selection must be cautious, and increased monitoring of fluid and electrolytes is advised.
Missed-dose rules If a dose is forgotten, it should be skipped if it is near the time for the next scheduled dose; doses must not be doubled.
Special procedural conditions The tablet must be taken in the morning.

Instruction Classifications (High-Level)

Category Classification
Administration method type Oral
Frequency pattern Once daily or Intermittent (alternate days)
Use-context constraints Use is constrained in severe renal impairment (creatinine clearance <10 mL/min), as the medication becomes ineffective.

Resulting Procedural Structure

The protocol begins with the oral administration of the tablet, usually at 12.5 mg or 25 mg, once daily in the morning, with food. Guidelines specify that any upward dose adjustment should occur gradually, typically no sooner than 2 to 4 weeks after initiation, allowing time for evaluation of the response. For conditions involving fluid retention, the drug's long duration allows for an intermittent schedule, such as taking a dose every other day. This structured administration protocol and dosing schedule are maintained by adhering to the specific dosing ceiling and the constraint against use in cases of severe kidney impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Clortalidona


Evidence for Use in High Blood Pressure (Hypertension)

Research into the use of Chlorthalidone for high blood pressure primarily relies on large-scale, long-term Randomized Controlled Trials (RCTs). This type of study is a high-quality study design for evaluating health outcomes over time. These major trials were designed to examine whether taking Chlorthalidone was associated with differences in the rates of serious, long-term health events when compared to a placebo or when compared to other major classes of blood pressure medications.

These studies explored important health outcomes, including the occurrence of major fatal and nonfatal cardiovascular events, such as stroke and myocardial infarction (heart attack). The findings describe patterns observed in these large trials, and the findings described that Chlorthalidone reported differences in the rates of these major cardiovascular outcomes in the populations studied. Researchers also monitored blood pressure readings over time.

Evidence for Use in Fluid Retention (Edema)

Chlorthalidone was evaluated in clinical pharmacology studies and early clinical trials to establish its action on fluid balance, which is the basis for its classification as a diuretic. These studies examined the drug's effect on temporary physiological imbalance, specifically its ability to increase the body's excretion of sodium and chloride. This research provides context for its evaluation in studies for fluid retention (edema).

This evidence contributes to the broader evidence landscape supporting the use of Chlorthalidone as an adjunct therapy for patients with pathological fluid retention linked to underlying conditions like Congestive Heart Failure or Hepatic Cirrhosis. Reported outcomes related to the measurement of physical swelling and fluid accumulation were recorded.

Key Limitations and Areas of Research Uncertainty

The broad evidence landscape, while extensive, contains several research limitation frames. One key limitation is that the comparative evidence is lacking in large, head-to-head RCTs that use equal dosage protocols when examining Chlorthalidone alongside other newer antihypertensive classes for some non-cardiovascular outcomes.

Additionally, data for certain groups remain insufficient, particularly for children and pregnant populations, as data are still emerging for these groups, as they were not the primary focus of the largest cardiovascular outcome trials. Therefore, long-term effects are not fully established in all patient groups, and research is ongoing.

Key Studies & References

  1. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  2. Diuretic Comparison Project (DCP): Chlorthalidone vs Hydrochlorothiazide in Improving CV Outcomes in Elderly Veterans With HTN
  3. Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival (SHEP long-term follow-up)
  4. Label: CHLORTHALIDONE tablet - DailyMed (FDA Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Clortalidona (FAQ)


Q: Can Clortalidona cause weight gain or weight loss?

A: Clortalidona is classified as a diuretic, meaning its intended purpose is to reduce excess body fluid volume, which can affect weight. However, official adverse reaction lists from regulatory sources do not typically specify weight gain or weight loss as a common or specified adverse effect.


Q: How quickly does Clortalidona start working to lower blood pressure?

A: The diuretic action of Clortalidona, which helps to lower blood pressure, is described in regulatory documents as starting approximately 2.6 hours after the tablet is taken. However, achieving the full therapeutic effect on blood pressure may take a longer period.


Q: What are the most commonly discussed side effects of Clortalidona in patient communities?

A: According to official adverse reaction tables, reactions listed as very common (meaning they affect 10% or more of patients) include low potassium (hypokalemia), high uric acid (hyperuricemia), and high lipids (hyperlipidemia). These metabolic changes are typical of this class of medication.


Q: Is it common for Clortalidona to affect sleep?

A: Official adverse reaction lists from regulatory agencies do not typically specify sleep disturbances or insomnia as a common or frequent effect. However, other effects on the nervous system, such as dizziness and headache, are reported.


Q: Can Clortalidona cause problems with blood sugar levels?

A: Official documents state that Clortalidona may cause an increase in blood glucose levels (hyperglycemia). It is also noted that latent diabetes mellitus (pre-existing, undiagnosed diabetes) may become apparent during administration.


Q: What is the longest period of time people typically take Clortalidona?

A: Clortalidona is generally prescribed for long-term management of chronic conditions, such as high blood pressure. Its effectiveness is described in official documents as being well sustained during continued use over many years.


Q: Do older adults react differently to Clortalidona compared to younger adults?

A: Official guidance states that dose selection in older adults is described as requiring caution. Studies suggest this population may have a higher risk of electrolyte abnormalities, such as low potassium (hypokalemia), and increased monitoring is advised.


Q: Can taking Clortalidona cause muscle cramps or weakness?

A: Yes, muscle cramps and muscle weakness are documented symptoms associated with potential electrolyte imbalances caused by the drug. Common imbalances, such as low potassium or low magnesium, can lead to these muscle-related issues.


Q: Is it necessary to have routine blood tests while taking Clortalidona?

A: Routine laboratory monitoring is recommended in official product information. Blood tests, including those to check electrolyte levels (like potassium and sodium) and kidney function, are recommended to be performed periodically.


Q: What is the main concern about Clortalidona affecting potassium levels?

A: The main concern is the potential for Clortalidona to cause low potassium levels (hypokalemia), a common side effect of diuretics. Official information indicates that hypokalemia can increase the risk of more serious adverse effects, including cardiac arrhythmias (irregular heartbeats).


Q: Can Clortalidona cause sensitivity to sunlight?

A: Yes, regulatory sources list photosensitivity (increased sensitivity to sunlight) as a potential adverse reaction. Official patient information generally includes advice to limit sun exposure and use protective measures like sunscreen.


Q: What is the typical research background for Clortalidona's use in chronic conditions?

A: The primary research background involves large-scale, long-term Randomized Controlled Trials (RCTs). These major studies focused on evaluating the drug's effect on rates of major cardiovascular events, such as stroke and heart attack.


Q: How long after starting Clortalidona should someone expect the full effect to be noticeable?

A: While the diuretic action begins quickly (within hours), the full blood pressure-lowering effect may take longer to develop. Official guidance for dose adjustments is often evaluated after 2 to 4 weeks to allow time for the full therapeutic response to be assessed.


Q: Does Clortalidona have an official safety classification during pregnancy?

A: Official documents advise that the drug may cause potential adverse effects in the newborn, such as jaundice or electrolyte imbalances. Use during pregnancy is generally not recommended unless the fluid retention (edema) is due to a pathologic cause.


Q: What types of foods or supplements are described as interacting with Clortalidona?

A: Official documents advise informing a healthcare provider of all nutritional supplements and herbal products used. Some herbal supplements, such as those with diuretic properties or those that affect potassium levels (e.g., licorice), may have potential interactions.


Q: Why is Clortalidona sometimes taken less often than once a day?

A: Clortalidona is chemically classified as a long-acting diuretic with a therapeutic effect that can last for 48 to 72 hours. This long duration of action supports the use of an alternate-day or intermittent dosing schedule for certain conditions like fluid retention (edema).


Q: What is the reason for avoiding alcohol while on Clortalidona?

A: Official information advises consulting a healthcare professional about the safe use of alcohol. Drinking alcohol while taking Clortalidona can worsen certain side effects, such as dizziness or lightheadedness.


Q: Do studies suggest Clortalidona helps reduce the risk of other heart-related issues?

A: Major research primarily examined the use of Clortalidona as part of a regimen to reduce the occurrence of major fatal and nonfatal cardiovascular events. These critical outcomes include stroke and myocardial infarction (heart attack).


Q: Can Clortalidona make you feel dizzy when standing up?

A: Yes, dizziness or lightheadedness can occur, particularly when getting up suddenly from a sitting or lying position. This is due to the potential for the medicine to cause orthostatic hypotension (a drop in blood pressure when standing), which is a documented side effect.


Q: Are there different brand names for the drug Clortalidona?

A: Yes, the active ingredient chlorthalidone is available under various brand names internationally, such as Hygroton and Thalitone, in addition to its generic form. It is also an ingredient in several combination medicines.


Q: What information is available about Clortalidona use in individuals with gout?

A: Official documents note that Clortalidona can cause high uric acid levels (hyperuricemia), which is a known risk factor for gout. Gout is listed as an uncommon adverse reaction, and patients with a history of the condition should inform their healthcare provider.


Q: Is Clortalidona officially approved for use in pediatric patients?

A: Official documents state that the safety and effectiveness of Clortalidona in pediatric patients have not been formally established. For this reason, it is generally not approved for use in this age group.


Q: What are the signs that Clortalidona is having its intended effect?

A: The intended effects are volume reduction and lowering blood pressure. A common physical sign that the medication is working is an increase in the frequency of urination. Consistent blood pressure monitoring is necessary to confirm the full therapeutic effect.


Q: Can Clortalidona cause changes to skin appearance?

A: Yes, changes to skin appearance are possible adverse reactions. Common documented effects include rash and hives (urticaria). More serious, but rare, reactions involving severe skin disorders have also been reported.


Q: Are there any specific lifestyle factors mentioned in official documents that affect Clortalidona's action?

A: Official guidance advises caution regarding alcohol consumption and sunlight exposure due to the potential for side effects to worsen. Additionally, a low-sodium diet is often mentioned as an important part of the overall treatment plan for high blood pressure.


Q: What happens if someone accidentally misses a dose of Clortalidona?

A: If a dose is missed, official instructions advise patients to skip the missed dose if it is almost time for the next scheduled dose. Official instructions specify that the dose should not be doubled at the next scheduled time.


Q: Is there a known limit to how high the blood pressure lowering effect of Clortalidona can be?

A: Official dosing guidance sets a maximum effective dose for treating high blood pressure. It is documented that increasing the dosage beyond a certain point usually does not significantly increase the effectiveness of blood pressure lowering but can increase the risk of side effects.


Q: Does Clortalidona interact with over-the-counter cold and flu medications?

A: Official guidance advises caution with many over-the-counter medications. Products containing sympathomimetic agents (often found in certain cold and flu medicines) should be used cautiously, as they can cause cardiovascular effects which may interact with Clortalidona.


Q: What is the research evidence for Clortalidona's use in individuals who have had a stroke?

A: Major research primarily examined the use of Clortalidona as part of a regimen to reduce the future occurrence of cardiovascular events, including stroke, in populations with high blood pressure. Its use is generally preventative in nature.


Q: Are there any known interactions between Clortalidona and herbal supplements?

A: Yes, official documents recommend informing a healthcare provider about all herbal products used. Some herbal supplements, particularly those with diuretic properties or those that affect potassium levels (e.g., licorice), may have potential interactions.


Q: Is Clortalidona sometimes prescribed as part of a combination pill?

A: Yes, Clortalidona is an active ingredient in various combination medicines that include other types of antihypertensive drugs. Examples include combinations with beta-blockers or angiotensin receptor blockers.


Q: What are the official recommendations about driving or operating machinery while taking Clortalidona?

A: Official safety information advises caution when driving or operating machinery if side effects such as dizziness or lightheadedness occur. This is particularly important when starting treatment or following a change in dosage.


Q: Are there any official statements about Clortalidona use in individuals with kidney conditions?

A: Clortalidona has been described as useful in managing fluid retention (edema) associated with certain forms of renal dysfunction, such as nephrotic syndrome. However, it is also advised that the medication must be used with caution in cases of severe kidney disease.


Q: What is the official information regarding the risk of dehydration with Clortalidona?

A: Official documents explicitly state that patients can easily become dehydrated while taking Clortalidona, as it increases fluid excretion. Dehydration is a risk that can lead to complications such as very low blood pressure or serious electrolyte imbalances.


Q: Why are people often told to monitor fluid intake while taking Clortalidona?

A: Monitoring fluid intake is advised because the drug affects the body’s fluid balance. Official warnings note that while adequate hydration is important, drinking too much liquid can be as unsafe as not drinking enough in some clinical scenarios.

How should Clortalidona be stored and disposed of?

How to Store and Dispose of Clortalidona

Clortalidona should be stored at room temperature, protected from excess heat, moisture, and direct light. Keep the medication in the original container, which must be tightly closed. It is important to keep this medicine from freezing.

To ensure safety, keep Clortalidona out of the sight and reach of children and always place it in a secure location. Many pill containers are not child-resistant, so safety caps must be locked immediately after use.

For disposal, do not keep expired or unused medicine. Unused Clortalidona should be disposed of by a drug take-back program when available. If a take-back program is not accessible, mix the medicine (without crushing the tablets) with an unappealing substance, such as dirt or used coffee grounds, and seal the mixture in a container before placing it in the household trash. Consult a healthcare professional or pharmacist for specific disposal advice.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clortalidona found in:

A-Z Index: